VOYDEYA™ is a prescription medication designed to address the debilitating effects of paroxysmal nocturnal hemoglobinuria (PNH), a rare blood disorder characterized by the breakdown of red blood cells outside of blood vessels (extravascular hemolysis). When used in conjunction with ravulizumab or eculizumab, VOYDEYA™ offers a valuable therapeutic option for adults suffering from this condition. 

Brandsymbol worked closely with the AstraZeneca team to develop the brand name, VOYDEYA™, and identify the company’s submission for this innovative treatment for PNH. The name’s “VOY” component conveys a sense of transformation and progress, aligning with the aspirational messaging of danicopan, “a voyage to a new day.”